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INTRODUCTION
rogrammed cell death (PCD) - apoptosis is a special type
of cell death essentially different from necrosis in nature and
biological significance. Apoptosis is an active process of geneti-
cally regulated cell autodestruct ion and in most cases has a
homeostatic function (1). Studies of the correlation of pro-
grammed cell death with proliferation and the multistage carcino-
genesis process are in the focus of modern research. A great
number of genes are known today, whose protein products take
part in regulation of the PCD process (2). Mutations and deletions
of apoptotic genes play important roles in carcinogenesis, tumor
growth, and tumor regression. Genes that have received the most
attention in this regard are bcl 2 and p53 (3). It is known that the
protein product of the bcl 2 gene plays role in the promotion of cell
survival and in the inhibition of apoptosis (4). The recognition of a
family of bcl 2 related proteins is also emerging that includes bax,
a conserved homologue of bcl 2. It has been established that bcl
2 and bax proteins play important opposing roles in the regulation
of apoptosis in many cell systems (5). Opposite to bcl 2, the wt
p53 gene encodes a tumor suppressor protein, which plays a cru-
cial role in cell cycle regulation and induction of apoptosis (6,7).
Experimental studies, both in vitro and in vivo, have shown the
capability of antineoplastic agents to induce the process of apop-
tosis (8-10). Studies conducted up to now on various models
systems (acute lymphoblastic leukemia, lymphomas, Mycosis
fungoideus, breast cancer, lung cancer, etc.) have shown that the
ability of antineoplastic agents to induce apoptosis of neoplastic
transformed cells represent a positive prognostic parameter in the
treatment of malignancy (11). The first attempts at following in
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BACKGROUND: The level of spontaneous apoptosis, the maximal response by apopto-
sis and the time when maximal apoptotic response is established are significant prog-
nostic parameters that correlate with the therapeutic response of patients with malig-
nant diseases. 
METHODS: Our study included 12 patients with B-CLL (I group of 7 patients) and ANLL
(II group of 5 patients). Detection of apoptotic parameters on semifine section of
peripheral blood was performed. Bcl 2 and mutated p53 expression were analyzed
using the monoclonal antibodies by APAAP techniques.
RESULTS: In our work, the established levels of spontaneous and therapy induced
apoptosis correlate with clinical response of patients. All patients were bcl 2 strongly
positive. Expression of p53 protein was not detected in these patients. The ultra struc-
tural analysis of the malignant cells has shown that a great number of cells react to
antineoplastic agents’ effect either by activating the cell response to stress or by apop-
tosis.
CONCLUSION: The results of our pilot study have shown that the established levels of
spontaneous and therapy - induced apoptosis are in correlation with the clinical
response of the patients to the applied therapy and that the measurable apoptotic para-
meters can represent prognostic parameters in treatment of hematologic neoplasms.
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55vivo the effects of chemotherapy by a number of authors showed
that the level of spontaneous apoptosis, the maximal response by
apoptosis and the time when maximal apoptotic response are sig-
nificant prognostic parameters that correlate with the therapeutic
response of patients with malignant diseases (12). 
In our study, the level of spontaneous apoptosis represents the
percentage of malignant cells that die by apoptosis without the
influence of antineoplastic agents. Maximal response by apopto-
sis is taken as the moment when the greatest percentage of cells
is included in apoptosis during the treatment of patients with anti-
neoplastic agents. The time needed to establish maximal
response by apoptosis is the period in which the maximal apop-
totic rate is achieved. Histopathological diagnosis, previous treat-
ment and response, duration of response, performance status of
patient, immunophenotype of tumor, cytogenetics of tumor (when
possible) represent clinically relevant data for analyzing PCD (11).
At the same time, resistance to antitumor treatment is also con-
sidered from the viewpoint of the loss of the capability of a certain
antineoplastic agent to induce apoptosis of malignant cell (13,14).
MATERIALS AND METHODS
Our study includes 12 patients with newly diagnosed B - chronic
lymphocytic leukemia - B-CLL (I group of 7 patients) and acute
non -lymphoblastic leukemia  - ANLL - M4 (II group of 5 patients).
The patients with B-CLL were treated by high dose - chrolambu-
cil (HD-CLB), while the patients with ANLL-M4 were treated by
intensive chemotherapy (Adryamicin, CytoAra and VP16).
Patients included in this study were treated on the Clinic of
Hematology, Military Medical Academy.
Technique for preparation of peripheral blood buffy coat cells for
electron microscopy. The effect of the applied therapy on the
induction of apoptosis was monitored by successive taking of
peripheral blood of the patient prior to the administration of the
therapy (to determine the level of spontaneous apoptosis) and
during the first 5 days of the therapy. Detection of apoptotic para-
meters on semifine sections of peripheral blood was performed.
The buffy coat cells in the peripheral blood of patients were
enriched by centrifugation (1200 rpm, 15 min) (15). The speci-
mens were fixed in 4% glutar-aldehyde buffered in 0.1 cacodylate
buffer (pH 7.4) and postfixed in 1% osmium tetroxide in the same
buffer. The specimens were dehydrated in a graded series of
alcohol and embedded in EPON 812. The semifine and ultrathin
sections were cut on the LKB ultramicrotome III. The semifine
sections were routinely stained by 1% toluidine blue in borax (16).
Samples were assessed under an optical microscope at a magni-
fication of 400x in immersion. At least 1000 cells in randomly
chosen fields were examined for each sample. The numbers of
apoptotic cells were presented as a percentage of the cell count.
The ultrathin sections stained with uranyl acetate and lead citrate
(17). Ultrastructural analysis of sections was performed on
Philips electron microscope 201C. 
Immunohistochemistry. Mononuclear cells from these peripheral
blood specimens were separated by centrifugation (1500 rpm,
30’) on Lymphocyte Separation Medium (Cat. No. 16-922-49,
ICN Flow) and washed in phosphate-buffered saline (PBS). These
specimens were used to prepare smears on microscopic slides.
All smears were air-dried at room temperature for at least 2 hours.
The cell smears were fixed in acetone for 10 minutes or methanol
for 4 minutes at 4…C, before immunohistochemical staining. The
antibodies used were monoclonal anti - bcl 2 antibodies, diluted
1:50 (DAKO A/S Denmark, Cat. No. M0887) and monoclonal anti
- p53 DO-7 antibodies, diluted 1:25 (DAKO A/S Denmark, Cat.
No. M7001). Slides were incubated for 24 hours with a dilution of
the primary mouse antihuman monoclonal antibodies. Slides
were washed twice with Tris buffered saline - TBS (this solution
was prepared by mixing one part of Tris - HCL buffer, 0.5M, pH
7.6 with nine parts of 0.15 M saline) and incubated with a 1:25
dilution of Mouse Immunoglobulins (DAKO A/S Cat. No. Z 0259)
for 30 minutes at room temperature. After rinsing in TBS, the
slides were incubated with a 1:25 dilution of APAAP Mouse
Monoclonal (DAKO A/S Cat. No. D0651) for 30 minutes at room
temperature. The slides were rinsed again in TBS and incubated
with chromogenic substrate (Tris buffer, 0.2M, pH 7.6, 50 ml;
Naphthol AS phosphate, free acid - dissolved in 0.5 ml N, N-
dimethylformamide, 15 mg; Fast red violet LB salt, 40 mg; 1 mM
Levamisole, 12 mg) for 45 minutes at the room temperature. After
chromogen development, the slides were washed in two changes
of water and counterstained with Meyers’s hemotoxylin for 4 min-
utes at room temperature. Finally, the slides were mounted with
Glycergel (18,19). For immunohistochemical analysis, frozen
sections of colonic carcinoma and normal tonsil tissue were used
as positive controls. In our study, the TBS solution was used as
a negative control. Samples were assessed under an optical
microscope at a magnification of 400x. At least 500 cells in ran-
domly chosen fields were examined for each sample. The data
obtained were arbitrarily grouped in four classes of positivity: I. +
(<20%), II. + + (between 20 and 70%), III. + + +  (between
70 and 90%), and IV.  + + + + (>90%).
RESULTS 
Quantitative analysis of measurable parameters of apoptosis. The
quantitative analysis of measurable parameters of apoptosis was
conducted on semifine sections obtained from the patients’
peripheral blood from both groups (Figure 1). 
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sections obtained from the peripheral blood of patients, taken
prior to the introduction of chemotherapy. The percentage of the
therapy-induced apoptotic cells was also determined on semifine
sections obtained from the patient’s peripheral blood that was
successively taken during the first five days of the therapy. In the
first group of patients with de novo discovered CLL, the level of
spontaneous apoptosis ranged from 11.39% to 20.50%. In the
group of ANLL-M4 patients it was significantly lower, and it
ranged from 1.50% to 7.12%. The maximal apoptotic response
was established with four patients with the CLL clinical diagnosis.
The shortest maximal apoptotic response time was marked with
a KM2 patient and it was 2 days. The maximal apoptotic response
time in two patients was 3 days. One patient reached the maximal
apoptotic response time of 4 days. A trend of growing number of
malignant cells dying in the process of apoptosis was recorded in
both analyzed groups of patients during the first five days of the
chemotherapy (Table 1).
The results of the electron microscopic analysis. The results of
the electron microscopic analysis of the buffy coat cells in the
peripheral blood of patients (taken prior to the therapy adminis-
tration and on the fifth day of the therapy). The malignant cells of
the analyzed samples dying in the process of apoptosis showed
typical morphological characteristics of this process, as
described by many authors (20-22). It is possible to monitor a
number of phases of the apoptotic process. The malignant cells
of the analyzed samples dying in the process of apoptosis, ini-
tially showed decreased volume and marginated, highly osmio-
philic chromatin. A total condensation of the nuclear chromatin
and the reduction the nuclear volume occur at the later phases of
the apoptotic process. The reduction of the nuclear volume is
accompanied with the reduction of the cytoplasmatic volume,
while all organelles remain intact (Figure 2). 
There are no morphologically clear differences between the cells
dying in the spontaneous or therapy-induced apoptosis. The
noted differences are more likely to be the differences in the mor-
phologic characteristics of the cells that enter the apoptotic
process, rather than the characteristics of the programmed cell
death. Malignant cells, which do not die in the apoptotic process,
on the fifth day of the therapy administration, show morphologi-
cal characteristics of intensive synthetic activity. They have
euchromatic nucleus and hypertrophic nucleolus. Dilated perinu-
clear spaces are a morphological sign of enhanced signal
exchange between the nucleus and cytoplasm. The signal
exchange is also made easier by the enlargement of the nucleus-
cytoplasmatic contact area, which is shown by the presence of
pseudoinclusions (pseudoinclusions were not recorded with CLL
cells, or with ANLL cells before the effect of the chemotherapy)
(Figure 3).
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Table 1. The spontaneous and therapy-induced apoptosis in patients with CLL
and ANLL
Figure 1. Semithin section of peripheral blood from patient with ANLL (day 5  of
the therapy) (1.000x)
Figure 2. Electron microscopic appearance of apoptotic CLL cell (day 5 of the
therapy) (16.000x)The results of the immunohistochemical APAAP method for
detection of protein products mut. p53 and the bcl 2 gene.
Protein products of the bcl 2 gene were detected in cell smears of
isolated mononuclear cells of the peripheral blood of the both
groups of patients (Figure 4). Simultaneously, the expression of
mutated p53 protein was not detected (Table 2).
DISCUSSION
By correlating the obtained values of the measurable apoptotic
parameters (the level of spontaneous apoptosis, maximal apop-
totic response and the maximal apoptotic response time) to the
clinical response of the patients to the applied therapy, it is pos-
sible to divide all the patients in three groups: 
a) Patients with the CLL clinical diagnosis, who achieved a com-
plete remission (CR) after the chemotherapy, and who had the
highest percentage of dying cells due to therapy-induced apopto-
sis; 
b) Intermediary values of measurable apoptotic parameters were
recorded in patients with the CLL clinical diagnosis, who are in
the condition of a partial remission (PR); 
c) The lowest values, both in spontaneous and therapy-induced
apoptosis, were recorded in patients with the ANLL clinical diag-
nosis, whose treatment had a lethal outcome. 
The results of our pilot study have shown that the established lev-
els of spontaneous and therapy-induced apoptosis are in correla-
tion with the clinical response of the patients to the applied ther-
apy and that the measurable apoptotic parameters can represent
prognostic parameters in treatment of hematologic neoplasms.
A comparison of malignant cells from the patients’ peripheral
blood taken prior the chemotherapy and on the fifth day of the
therapy, showed some morphological differences that can be
attributed to the effect of cytostatic drugs. This was particularly
noted with the analyzed peripheral blood samples of ANLL clini-
cally diagnosed patients. We think that the described ultrastruc-
tural finding of the intensive metabolic activity of malignant cells,
corresponds best with the morphological picture of cells with
activated cell response to stress. It should be also pointed out that
there is no significant morphological difference between the cells
dying in the spontaneous apoptosis from those dying in the ther-
apy-induced apoptotic process.
A high expression of the protein product bcl 2 gene was detected
immunohistochemically in all analyzed patients. The protein
expression of the bcl 2 gene blocks the apoptotic process in
patients with the ANLL clinical diagnosis and it represents a neg-
ative prognostic parameter in treatment of such patients. A chlo-
rambucil induced apoptotic process appeared in analyzed
patients with the CLL clinical diagnosis in spite of a high level of
immunohistochemically detected protein product bcl 2 gene. Our
results confirmed the numerous experimental studies of many
authors that the high and constant expression of bcl 2 gene in
CLL cells excludes the pathogenic role of bcl 2 oncogene in the
development of clones of neoplastic cells (23-25). Bcl 2 and bax
interaction, rather than the absolute level of bcl 2 expression, is
more important determinant of CLL cell apoptosis (26).
Simultaneously, a higher ratio of bcl 2 to bax protein is associat-
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Figure 3. Electron microscopic appearance of freshly isolated ANLL cell (day 5
of the therapy ) (11.200x)
Figure 4. Bcl 2 expression in CLL cells (1.000x)
Table 2. The results of the immunohistochemical APAAP method for detection of
protein products mut. p53 and the bcl 2 geneed with resistance to chemotherapy in CLL (27). The patients with
CLL clinical diagnosis had a good clinical response to the applied
therapy shown by a very short time in which they achieved a
remission stadium, which was successfully maintained.
Overexpression of bcl 2 blocks the apoptosis, and antineoplastic
agents must act downstream of bcl 2 (28). At the same time, the
absence of the protein product the mutated p53 gene in the
peripheral blood of patients with the CLL clinical diagnosis is in
correlation with their clinically good response to the therapy
received. In the analyzed group of the ANLL clinically diagnosed
patients, the expression of the protein product of the mutated p53
gene was not detected by the immunohistochemical method. The
absence of the mutated p53 gene protein product does not nec-
essarily mean that the functionally active protein product of the wt
p53 gene is present. For example, cellular protein mdm 2 can
inhibit the activity of the wt p53 gene (13,29,30). Functional inac-
tivation of the protein product of the wt p53 gene, and not only the
mutation of the p53 gene can be the reason for the low level of
the spontaneous and therapy induced apoptosis in the ANLL clin-
ically diagnosed patients. In 1996, Thomas et al., proved that the
apoptotic process in the CLL cells was independent with the p53
gene. According to these authors, the main mediator of the apop-
totic process in the CLL cells is the bax gene protein product. The
discovery of new members of the bcl 2 gene family - bcl x, bad,
bak, bag, bik  and their influence on the programmed cell death
makes this process even more complicated. Some of which are
anti-apoptotic, whereas other members of the family, such as bax
display pro-apoptotic function (28,31). 
CONCLUSION
Various experimental discoveries, as well as the results of our
work, show that monitoring of the spontaneous and therapy
induced apoptosis level, and of the prognostic parameters in the
treatment of hematologic neoplasms, must be extended both to
more members of the bcl 2 gene family and the p53 related
genes.  
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